Orthocell Ltd (AU:OCC) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Orthocell Ltd (ASX: OCC) has requested a trading halt on its securities pending an important announcement regarding the regulatory study results necessary for FDA market approval of its product, Remplir, in the US. This strategic pause aims to manage market expectations and ensure investors are well-informed. The halt will remain effective until the announcement is made or until normal trading resumes on December 3, 2024.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.